摘要
Paget病，以骨骼一个或多个区域破骨细胞介导的骨吸收增加伴有骨骼修复不良，进而导致骨重建失调和骨转换增加为主要特征。发病具有一定的年龄和地域差异，我国少见。其发病受环境和遗传的影响。目前，双膦酸盐是Paget病的主要治疗药物。通过多种途径抑制骨吸收从而达到治疗目的。唑来膦酸盐是第三代双膦酸盐，给药方式为单剂注射，临床实验证明能快速持久地缓解病情，具有高效性和安全性，并能提高患者生活质量，具有良好的应用前景。
Paget disease of bone is a chronic affliction of the adult skeleton featuring one or more areas of aggressive osteoclast-mediated bone resorption preceding imperfect osteoblast-mediated bone repair. Its morbidity depends on age and area, and there＇s few patient in China. Zoledronic acid, which belongs to the third generation of bisphophonate, can heal Paget disease well with single infusion and improve the quality of life. It approves to be safe and effective in Paget disease, and able to achieve prolonged remissions. It may result in more complete control of disease activity than has previously been possible.
出处
《中华骨质疏松和骨矿盐疾病杂志》
2009年第2期149-151,共3页
Chinese Journal Of Osteoporosis And Bone Mineral Research
